Padagis launches AB-rated generic version of Zomig Nasal Spray
17 November 2021 -

Padagis, a US-based pharmaceutical manufacturer that offers generic Rx and OTC products, announced on Tuesday the first-to-market launch of an AB-rated generic version of Zomig Nasal Spray.

The product is distributed in a unique unit dose presentation and is used to treat migraine headaches with or without aura in adults and paediatric patients (12 to 17 years of age).

Padagis president and chief executive officer, Sharon Kochan, said, 'This first-to-market launch is our second major product launch as an independent organisation since our separation from Perrigo in July and highlights our ongoing commitment and capabilities to develop, manufacture and commercialise high quality, high value alternatives in important treatment categories. The Padagis team continues to leverage our unique and specialised manufacturing technologies and development expertise to deliver valuable products to our customers and patients.'